Radiation After Failed Radical Prostatectomy

The NCCN Guidelines are continuously updated to reflect the newest standards of care in oncology. With the increased pace of cancer research, the breadth of disease sites, the emergence of new diagnostic markers and imaging techniques, and the explosion of new treatment options clinicians are challenged to keep up with these advances. The new treatment options for prostate cancer include minimally invasive surgical procedures, new classes of cytotoxic agents, and novel biologically targeted agents. Therefore, there is a great need for clinicians to maintain and continually add to their knowledge of scientific concepts and how those concepts can be applied in the everyday practice setting.  This program will focus on management of advanced disease.

Target Audience

This educational activity is designed to meet the needs of physicians, nurses, pharmacists, and other clinical professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Evaluate available clinical evidence for the management of hormone-sensitive advanced prostate cancer
Additional information
Supporters: 

Supported by an educational grant from Bayer HealthCare Pharmaceuticals and Algeta US

Course summary
Available credit: 
  • 0.25 Participation
  • 0.26 Nurse
  • 0.25 Pharmacist
  • 0.25 Physician
Course opens: 
06/28/2013
Course expires: 
03/01/2014
Cost:
$0.00

James L. Mohler, MD
Roswell Park Cancer Institute

Available Credit

  • 0.25 Participation
  • 0.26 Nurse
  • 0.25 Pharmacist
  • 0.25 Physician

Accreditation Period

Course opens: 
06/28/2013
Course expires: 
03/01/2014

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video and audio playback
  • Adobe Reader for certificate viewing/printing